List of EORTC trials

This page is a list of EORTC clinical trials sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).

Breast cancer

• EORTC 10085 – characterization of male breast cancer
• EORTC 10863 – continuous tamoxifen versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate
• EORTC 10951 – exemestane versus tamoxifen

Older studies

• Nafoxidine versus ethinylestradiol
• Levodopa versus nafoxidine

Prostate cancer

The following prostate cancer trials have been conducted, among others:

• EORTC 30761 – cyproterone acetate 250 mg/day versus medroxyprogesterone acetate 200 mg/day versus diethylstilbestrol 3 mg/day
• EORTC 30762 – estramustine phosphate 280 mg/day (560 mg/day initially) versus diethylstilbestrol 3 mg/day
• EORTC 30805 – orchiectomy versus orchiectomy plus cyproterone acetate (150 mg/day) versus low-dose diethylstilbestrol (1 mg/day)
• EORTC 30843 – orchiectomy versus buserelin versus buserelin plus cyproterone acetate (150 mg/day)
• EORTC 30853 – orchiectomy versus goserelin plus flutamide (750 mg/day)
• EORTC 30892 – flutamide monotherapy (750 mg/day) versus cyproterone acetate (300 mg/day)
• EORTC 30903 – prednisone versus flutamide
• EORTC 30954 – intermittent combined androgen blockade (with GnRH agonist plus bicalutamide (50 mg/day))
• EORTC 30958 – intermittent combined androgen blockade

References